Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) shares dropped 8.8% during trading on Tuesday . The company traded as low as $79.97 and last traded at $80.21. Approximately 82,870 shares were traded during trading, a decline of 47% from the average daily volume of 156,157 shares. The stock had previously closed at $87.91. Analysts […]
Isthmus Partners LLC lifted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 4.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,347 shares of the biotechnology company’s stock after purchasing an additional 1,530 shares during the period. Isthmus Partners […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Nancy Ryan Gray sold 934 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $83.20, for a total value of $77,708.80. Following the completion of the transaction, the director now owns 5,633 shares in […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) CFO Octavio Espinoza sold 5,873 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $86.01, for a total value of $505,136.73. Following the completion of the transaction, the chief financial officer now directly owns 23,882 […]
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) CFO Octavio Espinoza sold 5,156 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $86.66, for a total transaction of $446,818.96. Following the sale, the chief financial officer now owns 23,379 shares of […]